科兴制药：GB10注射液开展临床试验获批准

Core Viewpoint - The announcement indicates that the company’s wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for the GB10 injection, aimed at treating neovascular age-related macular degeneration [1] Group 1 - The product name is GB10 injection, and the acceptance number is CXSL2500841 [1] - The approval conclusion states that the product is allowed to proceed with clinical trials for the treatment of neovascular age-related macular degeneration [1]